SCHEMBL24641663

SCHEMBL24641663

c1ccc(CCNCc2ccc(N3CCOCC3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
GAA P10253 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.51
LMNA P02545 1/20 0.50
OGA O60502 1/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 1/20 0.49
HTT P42858 1/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA9 Q16790 1/20 0.48
HTR5A P47898 1/20 0.47
PLK4 O00444 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18179875 0.86 RAB9A (0.58) MAPTGAAL3MBTL1LMNARAB9A
SCHEMBL25291736 0.84 LMNA (0.64) MAPTGAAL3MBTL1LMNARAB9A
SCHEMBL24641978 0.84 MAPT (0.56) MAPTGAARAB9ANPC1BCHE
SCHEMBL9764527 0.83 SIGMAR1 (0.48) MAPTGAAL3MBTL1RAB9ASMN1; SMN2
SCHEMBL29939233 0.81 ALDH1A1 (0.53) MAPTGAAL3MBTL1LMNARAB9A
SCHEMBL24642104 0.81 L3MBTL1 (0.62) MAPTGAAL3MBTL1LMNAOGA
SCHEMBL27093513 0.80 GAA (0.55) MAPTGAAL3MBTL1OGAHTT
SCHEMBL28287211 0.80 SIGMAR1 (0.60) MAPTLMNARAB9ASMN1; SMN2NPC1
SCHEMBL3272134 0.79 GAA (0.91) MAPTGAABCHEALDH1A1KDM4E
SCHEMBL11881258 0.79 GAA (0.91) MAPTGAABCHEALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115215823-B FXR modulator, preparation method, pharmaceutical composition and application thereof 北京百思致道管理顾问中心(有限合伙) 2024-07-26 CN disclosed
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) 2024-07-18 US disclosed
EP-4324825-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Beijing Best Pathway Management Consulting Center (Limited Partnership) (CN) 2024-02-21 EP disclosed
CN-115215823-A FXR (FXR) regulator and preparation method, pharmaceutical composition and application thereof 青岛睿吉医疗技术有限公司 2022-10-21 CN disclosed
WO-2022218440-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 青岛睿吉医疗技术有限公司 2022-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF SLC10A1, NR1H4, FXR1 MAPT 464/4885GAA 2236/4885L3MBTL1 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.